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In children, aplastic anemia (AA) is a common com-
plication associated with fulminant hepatic failure
(FHF). The objective of this study was to determine
whether specific pretransplantation clinical and labo-
ratory characteristics can be used to distinguish be-
tween patients with FHF who are at higher risk of
developing AA. We performed a retrospective case–
control study to evaluate the clinical and laboratory
characteristics of those patients who presented with
evidence of FHF and eventually developed aplastic ane-
mia. We identified nine patients with AA, and all had
the indeterminate form of FHF and underwent liver
transplantation (LTx). The AA patients were compared
with a control group of 47 patients with indeterminate
FHF that underwent transplantation and did not de-
velop AA. We found that males were over-represented
in the group of patients that developed AA (p = 0.01).
Furthermore, during the pretransplant period, the AA
group had a significantly lower white count (p = 0.005),
absolute lymphocyte count (p = 0.004), and platelet
count (p = 0.019) when compared with controls. We
conclude that evidence of early bone marrow dysfunc-
tion is apparent before liver transplantation and the
development of AA in a subset of patients with the
indeterminate form of FHF.
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Introduction
Fulminant hepatic failure (FHF) is defined as severe liver
injury with onset of encephalopathy within 8 weeks af-
ter the onset of jaundice and in the absence of preexist-
ing liver disease (1,2). Fulminant hepatic failure may re-
sult from a variety of causes including infectious hepatitis,
toxin or drug-induced injury, metabolic diseases, or an in-
determinate (IFHF) form in which the etiology is unknown
and could not be established (3). The causes of FHF vary
geographically and are also age-dependent. In the United
Kingdom the most frequent pediatric cause of FHF is ac-
etaminophen toxicity, whereas most children in the United
States have the indeterminate type (4–6). Liver transplan-
tation (LTx) remains the only definitive mode of treatment
for individuals with FHF who fail to recover spontaneously.
Although LTx has drastically improved survival in patients
with FHF with 1-year survival rates that approach 90%,
various complications influence long-term morbidity and
mortality (7–9).
Aplastic anemia (AA) is a well-described occurrence follow-
ing LTx in patients with FHF, and typically presents within
3–4 months after the onset of the first clinical symptoms of
FHF. Since the first report of AA after FHF in 1987 by Stock
et al. (10), it has become increasingly apparent that it is
primarily observed in children with the indeterminate type
of FHF following LTx (11–13). A recent review of 31 case
reports showed the mean incidence of AA following IFHF
was 23%, with a mean age of 10 years and a male/female
ratio of 4.6 (11). There is a high morbidity and mortality rate
associated with these patients from bleeding and infection
owing to pancytopenia. Unfortunately, AA in patients with
IFHF remains poorly understood, as there are no published
reports comparing these patients with age-matched con-
trols. The objective of this study is to determine whether
specific pretransplantation clinical and laboratory charac-
teristics can be used to distinguish between patients with
FHF who are at higher risk of developing AA.
Methods
In addition to our existing database of liver transplant patients, the Inter-
national Classification for Diseases, Ninth Revision (ICD-9), code for acute
liver failure (ICD-9 #570) was reviewed for all admissions of pediatric pa-
tients (0–18 years of age) in order to further identify any additional patients
presenting with FHF to the UCLA Medical Center between January 1985
and December 2002. The UCLA human subjects’ review board approved
the study.
The criteria used to diagnose patients with FHF were the development
of abnormal liver synthetic function and hepatic encephalopathy within 8
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weeks of onset of jaundice, in the absence of known pre-existing liver dis-
ease (14). A series of laboratory tests were obtained in all patients described
in this study. They included HA total and IgM, HBsAg and Ab, HBcAg Ab,
HIV 1 and 2 Abs, CMV IgG/IgM, and EBV-VCA IgG/IgM. HCV Ab has been
assessed in all cases since the early 1990s and HCV qualitative blood RNA
assay has been performed in recent years. Depending on the age of the
patient, routine analysis for various infectious agents were generally per-
formed including HSV 1 and 2 IgG/IgM, enterovirus and Adenovirus culture,
and CMV urine culture in most neonates. HHV-6 IgG/IgM and Parvovirus
B19 IgG/IgM were frequently performed.
Urine organic acid and serum amino acids were routinely assessed in
neonates and most young infants, and galactosemia results were available
as part of the state-wide screen. Serum lactate, pyruvate, ferritin, alpha-1-
antitrypsin level and phenotype levels were routinely assessed in children
during early infancy. Patients in early and late childhood ages were routinely
assessed for serologic evidence of autoimmune hepatitis (ANA, anti-SM,
pANCA, anti-KLM) and for evidence of Wilson’s disease (serum and urinary
copper and ceruloplasmin). Serum acetaminophen and acetylsalicylic acid
levels were routinely tested when clinically indicated, and careful assess-
ment to exposure to a variety of drugs including valproic acid, isoniazid and
halothane was generally obtained. Only in the absence of all of the above
clinical entities was the designation of IFHF used (5).
Patients diagnosed with AA following FHF were identified by searching
for the ICD-9 code #284 for AA in discharge summaries of all hospital-
ized pediatric patients at the UCLA since 1985. Those patients were then
cross-matched to our pre-existing UCLA database of pediatric patients who
presented with FHF. All AA patients had hematological studies and bone
marrow pathology that confirmed the diagnosis of AA as defined by the In-
ternational Aplastic Anemia Study Group criteria: depression of two of three
peripheral blood counts (granulocytes < 0.5 × 109/L, platelets 20 × 109/L
or reticulocytes < 1%) in the presence of hypocellular bone marrow (15).
The date that the diagnosis of AA was established is reported as the period
between LTx and the day that the CBC results met IAASG criteria for AA.
All patients who met IAASG criteria underwent bone marrow biopsy, and
the diagnosis of AA was only applied to those patients who had evidence
of hypocellular bone marrow. Management of AA included administration
of granulocyte-colony stimulating factor (G-CSF) and reduction of immuno-
suppression. Antithymocyte globulin (ATG) as well as a continuing steroid
regimen was used in the management of several patients. Medications that
had the potential to cause bone marrow suppression were discontinued
when AA became clinically suspicious. Unless higher blood counts were
clinically indicated, packed red blood cells and platelets were transfused to
maintain a hemoglobin level > 7 g/dL and platelet count > 20 × 109/lL.
Medical records for each subject were reviewed and pertinent clinical and
laboratory data were obtained, which included: sex, age, date of admission
and discharge, date of transplant, and laboratory data. Laboratory data com-
Table 1: General characteristics of patients with aplastic anemia after acute liver failure
Patient Age (y) Sex Time to LTx (days) Time from LTx to AA (days) Season/year of presentation Survival BMT
1 7.9 M 10 23 Winter/1990 Y Y
2 1.9 M 1 17 Winter/1993 Y N
3 4.8 M 19 12 Fall/2001 N N
4 9 M 5 151 Summer/2000 Y Y
5 1.4 M 4 26 Spring/2001 Y N
6 12.9 M 4 80 Winter/2001 Y N
7 2.3 M 1 37 Winter/1999 N N
8 14.3 M 13 25 Fall/2001 Y N
9 1.3 M 5 13 Winter/2003 Y N
prised of hepatic and hematologic parameters were obtained from each
subject at the time of admission to the UCLA. In addition, hematologic pa-
rameters consisting of platelet and white blood cell counts were followed
from the date of transplant to 4 weeks post-LTx.
Statistics
Univariate analysis was undertaken using a Student’s t-test for continuous
variables, while categorical variables were analyzed using the Chi-square
test. A p-value of 0.05 was considered statistically significant.
Results
General characteristics
Since 1985 a total of 272 children have been admitted to
the UCLA Medical Center for evaluation and treatment of
FHF. A total of 110 patients were diagnosed with the in-
determinate form of FHF and 66 of these patients were
transplanted with a survival rate of 86%. The nine patients
who developed AA were all from this group of patients who
underwent LTx for the indeterminate form of FHF. The con-
trol group consisted of 47 patients with IFHF who survived
LTx beyond 4 weeks of transplant. Nine patients, who died
within this time period, and one patient whose medical
records were not available for review were excluded from
the study. None of the nine patients who died within 4
weeks of LTx had evidence of pancytopenia.
Aplastic anemia developed in only 3.3% (9/272) of all pa-
tients with FHF, and in 8.2% (9/110) with the indeterminate
form of FHF. Of the patients who were transplanted for
IFHF, 13.6% (9/66) developed AA. Of the 44 patients with
IFHF who were not transplanted, 45% survived. Aplastic
anemia was not seen among the 20 patients who recov-
ered from FHF in the absence of LTx. The association be-
tween LTx and the development of AA approached statis-
tical significance (p = 0.07) when evaluated by Chi-square
analysis.
Aplastic anemia
Aplastic anemia developed post-transplant in nine patients
who underwent liver transplantation for IFHF. Table 1
shows the general characteristics of the patients in whom
AA developed. Comparison was made between the aplas-
tic anemia group (n = 9) and the control group (n =
47). All patients with AA were male and were therefore
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overrepresented when compared with the control group
(24/44, 54% males, p = 0.01). The average age for those
who developed AA was 6.2 ± 1.7 years of age, compared
with 6.0 ± 0.8 years (p = 0.91). The mean time between
date of LTx and onset of AA in these patients who met the
IAASG criteria for AA was 42 ± 15.2 days post-LTx. Biop-
sies confirmed the presence of hypocellular bone marrow
in all cases. The time from admission to LTx was similar be-
tween the two groups: 6.9 ± 2 and 9.6 ± 2.5 days for the
AA and controls groups, respectively (p = 0.41). Review
of admission dates suggests a trend towards a recent in-
crease in the number of patients with FHF who develop
AA, with six patients presenting during a 20-month period
beginning in the spring of 2000 (Table 1).
Two patients died without ever entering remission for AA
(Table 1). Patient 3 died of multisystem organ failure 25
days after undergoing his second LTx. Graft vs. host dis-
ease and acute cardiopulmonary arrest developed in pa-
tient 7 who died 82 days post LTx. Patients 1 and 4 re-
ceived bone marrow transplants as treatment for their AA
and both patients survived and recovered uneventfully.
Hepatic and hematological markers on admission
For both groups, we compared the hepatic and hemato-
logical laboratory studies obtained on the day of their ini-
tial admission to the UCLA for liver failure (Table 2). Hep-
atic markers included albumin, AST, ALT, total and conju-
gated bilirubin ammonia, fibrinogen, and prothrombin time.
Hematological parameters examined were white blood cell
count (WBC), platelets, hemoglobin, absolute neutrophil
count (ANC), and absolute lymphocyte count (ANL). Retic-
ulocyte count was rarely obtained in patients on the day of
admission and was therefore not evaluated.
While the patients with FHF who developed AA had a lower
ammonia level (p = 0.04) on the day of admission, none
of the other values in the liver panel from the first day of
admission approached statistical significance between the
two groups (Table 2). In contrast, the hematological param-
eters in the AA group displayed a significantly lower white
blood cell count (6.2 × 103/lL vs. 10.5 × 103/lL, p = 0.005)
and platelet count (125 × 103/lL vs. 202 × 103/lL, p =
0.019) on admission compared with the control group (Ta-
ble 2 and Figure 1). Analysis of the mean absolute lympho-
cyte count on admission between the two groups revealed
a significant difference (1.6 × 103/lL vs. 3.4 × 103/lL, p =
0.004). Hemoglobin and absolute neutrophil counts were
not found to be substantially different between the two
groups.
Trends in hematological markers
We compared the mean WBC and platelet counts for the
first 4 weeks after liver transplant in the AA-IFHF and IFHF
groups (Figure 1A,B). A consistent elevation of the WBC
count marked the initial (first week) post-transplant pe-
riod in both groups. The mean WBC levels between the Ta
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Figure 1: (A) Mean platelet and (B) white blood cell counts
post liver transplant for the aplastic anemia indeterminate
fulminant hepatic failure (AA-IFHF) and IFHF groups. (C) Rate
of change in WBC post liver transplant for the AA-IFHF and IFHF
groups.
groups were significantly different during the entire 28-
day follow-up period with the exception of day 2 and day
15, where the mean difference was not of statistical sig-
nificance. Similarly, the trend in platelet counts between
the two groups was significantly different over the same
time period (Figure 1B). The platelet count in the control
patients gradually increased to normal levels a week after
the liver transplantation, while the platelet count in the AA
group never improved during the immediate postoperative
period. Post-operative absolute reticulocyte count was sig-
nificantly lower in the AA group (3.1 × 104 ± 1.2 × 104)
when compared with the controls (1.3 × 105 ± 1.6 × 104,
p < 0.00003).
To determine the rate of change in WBC during the post-
operative period, we analyzed the log-base 10 of the white
blood cell counts for both groups during three different
time periods. All time periods began from the initial date
of transplant and ranged from 1–3 weeks post-LTx. Lin-
ear regression analysis was performed, generating a linear
trend-line through the data points. The slope of each trend-
line was calculated and the mean was compared between
the AA and control groups. The aplastic anemia group was
found to have a significant decline in WBC counts between
0 and 2 weeks (− 0.009 vs. 0.017, p = 0.023) and 0–3
weeks (− 0.023 vs. 0.003, p = 0.004) post-LTx (Figure
1C). No significant difference was observed during the first
week post-LTx in the rate of decline.
Discussion
This study represents the first published case–control
study evaluating the clinical characteristics of patients who
develop aplastic anemia following acute liver failure. In our
study, the development of AA after LTx for IFHF occurred
generally in young children (mean age 6.2 years). This find-
ing is similar to that reported previously where the mean
age was approximately 10 years of age (11,16,17).
We provide evidence that male patients are at significantly
higher risk for developing AA after transplant. While males
represented 54% of the control group, all the patients in
the AA group were male (p < 0.01), and 27.3% (9/33) of
the males in the group transplanted for IFHF were diag-
nosed with AA. This finding is consistent with case reports
that have described a predisposition of males among those
patients who develop AA following LTx, however, gender
differences have not been described in other established
causes of AA (16,17).
It has been speculated that AA associated with IFHF is the
result of an infectious etiology by a yet to be identified in-
fectious agent. While parvovirus has been associated with
the development of aplastic anemia, as well as FHF, we
failed to identify any cases of parvovirus by serology in
our patients. However, suggestive of a viral etiology is the
fact that we have detected a recent increase in the num-
ber of patients that we have encountered over the last 2
years (Table 1). Of note is the overall distribution at time of
presentation between the AA and control groups, demon-
strating a recent clustering of patients presenting with AA
over a 20-month period without a significant change in the
control group.
In our study, aplastic anemia was diagnosed only in those
patients who underwent LTx for IFHF. Of the patients who
were transplanted for IFHF, 13.6% (9/66) developed AA.
This finding is in contrast to the higher rate of occurrence
reported by Tzakis et al. and Cattral et al., where 28%
of 32 patients and 33% of 18 children transplanted for
IFHF developed AA, respectively (16,17,17). In another se-
ries, three of 10 patients who survived LTx for IFHF had
evidence of AA postoperatively (18). The question arises
of whether or not there would have been further cases
of AA that would have developed in those patients who
did not survive LTx or did not survive long enough to be
transplanted, especially considering greater than 50% of
the patients from the nontransplanted group with IFHF
died.
In our data series, there is no evidence of AA develop-
ing in patients transplanted for other causes of FHF or in
the non-LTx patients with IFHF. All nine patients who de-
veloped AA had been transplanted for IFHF. A potential
correlation between AA and liver transplant was observed
in this study. Comparison of these nine patients with
the 20 patients with IFHF who survived without requiring
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transplantation approached statistical significance (p =
0.07) when evaluated by means of Chi-square analysis.
While this may suggest that AA in this patient popula-
tion may be a complication of the transplantation proce-
dure, this study indicates that those patients who even-
tually develop AA have subtle evidence of bone marrow
dysfunction before the time of liver transplantation. This
implies that the process of transplantation is not causative
to the development of AA although LTx and ensuing med-
ical treatment may contribute to or hasten the develop-
ment of AA. It is more likely that patients with IFHF who
develop AA inherently go on to require transplantation. In
other words, these patients who would eventually develop
AA fail to improve their liver function spontaneously, there-
fore necessitating a liver transplantation. While this study
did not identify significant differences in the hepatic func-
tion between the two groups at the time of admission, we
have not evaluated trends in liver function between the
two groups during the initial hospital stay.
In this study, AA was diagnosed by bone marrow biopsy
at a mean time of more than 2 months after admission for
FHF. Although liver panels on admission were not found
to predict the development of AA, lower levels of both
WBC and platelet counts were found to correlate with the
risk of developing AA post-transplant. Interestingly, while
there was no significant difference in the absolute neu-
trophil count, there proved to be a lower mean absolute
lymphocyte count in the AA-IFHF group compared with the
control group. This most likely is caused by the same etio-
logic agent or process that caused the fulminant liver failure
to develop. It is unclear if this is owing to direct cytotoxic
effects from a yet to be identified infectious agent or au-
toimmune mechanism induced at the time of liver failure.
Our data strongly suggests this process is initiated before
transplantation of the new liver, thus making it unlikely that
the procedure or accompanying medications play anything
more than perhaps a contributory role to the process. The
effect on all three hematopoietic cell lines is suggestive of
a cytotoxic effect on either stem cells or early pluripotent
progenitor cells. If this is so, it would make the strategy of
storing autologous marrow or peripheral blood stem cells
before the liver transplant for future stem transplantation
ineffective. However, as the vast majority of patients re-
cover bone marrow function in the absence of bone mar-
row transplantation, residual stems cells must be present,
albeit in insufficient levels to quickly repopulate the mar-
row. This study defines the general characteristics of chil-
dren at risk of developing AA following FHF, and it may
allow for either earlier intervention in the search for a po-
tential bone marrow donor, or implementation of immuno-
suppressive therapy for treatment of AA. Nevertheless,
further studies are needed to assess the characteristics
of the various immature and mature lineages in the bone
marrows of these patients.
The WBC and platelet counts were analyzed for a period of
4 weeks following LTx and the data demonstrated evidence
of early bone marrow dysfunction before establishing the
diagnosis of AA by bone marrow biopsy. During our anal-
ysis of the WBC data, we noticed a consistent elevation
in the white counts during the immediate postoperative
period for both groups of patients. The etiology of this el-
evation is likely of multifactorial origin, and may include
stress, postoperative infections, and the use of steroids as
part of the immunosuppressive regimen. Aside from this
transient elevation, the white counts postoperatively were
clearly different between the AA and control groups (Figure
1A,C). In contrast to the controls, the WBC count of the AA
group did not return to baseline after the post-LTx eleva-
tion, but steadily declined over the 4-week period, dropping
to less than 1000/lL. In fact, the rate of change of the WBC
count during the initial weeks post-transplant was signifi-
cantly different between the two groups. Specifically, the
AA group had a progressive decline in the WBC counts, in
contrast to the WBC counts in the control group after the
first 2 and 3 weeks post-transplant.
In summary, IFHF is the most commonly diagnosed cause
of fulminant hepatic failure in pediatric patients presenting
to the UCLA, accounting for 40% of all cases since 1985. In
children, AA is an occasional yet severe complication that
frequently occurs concurrently in patients with IFHF. More-
over, the incidence may have been significantly higher than
reported previously, as some of our patients may have died
before clear laboratory evidence of AA developed. Young
males appear to be at highest risk for the development of
AA after transplantation for fulminant liver failure of the in-
determinate type. In addition, we have identified early clin-
ical trends such as the difference in the profile of WBC and
platelet counts before and post-LTx in patients developing
AA after IFHF. Our data suggests that levels of lymphocyte
and platelet on admission, and during the immediate post-
operative period, may help distinguish those patients at
risk of developing subsequent AA. Further studies to iden-
tify additional laboratory and clinical predictors will facilitate
early identification of ‘at risk’ individuals. This will allow for
early initiation of the donor search process in anticipation
of possible need for hematopoietic stem cell transplant.
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